ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0226

Global Ultrasound Scoring Systems for Assessing Synovitis in Rheumatoid Arthritis
Abstract Number: 0728

Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis
Abstract Number: 2576

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 2141

Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Abstract Number: 0810

Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation
Abstract Number: 2486

Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Abstract Number: 1599

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study
Abstract Number: 1600

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study
Abstract Number: 1812

Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Abstract Number: 1289

Gout Education for Primary Care Providers: A Scoping Review
Abstract Number: 2006

Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
Abstract Number: 1992

Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Abstract Number: 1996

Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
Abstract Number: 1912

Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Abstract Number: 0422

Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].